Ushering in a new era of cancer care
Fuzionaire Theranostics’ pipeline includes combinations of therapeutics and PET imaging diagnostics.
We are developing complementary drug pairings to image and treat cancer. Our HetSiFA® platform enables such drug pairings, which target the same marker or receptor expressed on a tumor, to include the scalable PET diagnostic radionuclide fluorine-18 and any of the leading alpha- and beta-emitting therapeutic nuclides. The pairings can also be identical chemical twins that distribute the same way in patients, and can be designed to bind to two different targets expressed on tumors.
Discovery
Lead Optimization
First-In-Patient
Clinical Phase I-III
Proof of concept (target SSTR)
Discovery
Lead Optimization
First-In-Patient
Clinical Phase I-III
18F PET
companion
companion
End PoC study
FTX-TATEs are analogs to FDA-approved
177Lu-DOTA-TATE with the added benefit that the
18F PET companion and the
177Lu therapeutic are identical chemical twins. Commercial-scale manufacturing of several
18F-FTX-TATEs was implemented at four radiopharmacies. PET imaging and BioD in rodents confirmed stability and favorable biodistribution properties. The FTX-TATE proof-of-concept study was successful and is concluded.
Prostate cancer (target GRPR)
Discovery
Lead Optimization
First-In-Patient
Clinical Phase I-III
18F /
225Ac theranostic pair
Our first development program aims to improve the theranostic care of patients with metastatic prostate cancer (mPCa). Recent advances in nuclear medicine have improved and prolonged lives by targeting the prostate-specific membrane antigen (PSMA), but
this approach does not benefit some patients. Our
18F /
225Ac theranostic pair targets the gastrin-releasing peptide receptor (GRPR) in mPCa to complement available PSMA treatments.
Prostate cancer (target GRPR/PSMA)
Discovery
Lead Optimization
First-In-Patient
Clinical Phase I-III
18F / tba
theranostic pair
theranostic pair
With our program developing a dual-targeting theranostic for PSMA- and/or GRPR-positive mPCa, we aim to treat mPCa patients irrespective of the underlying tumor biology. The
18F diagnostic would also be a valuable tool for more accurately staging a wider group of prostate cancer patients.
Undisclosed (target GRPR/tba)
Discovery
Lead Optimization
First-In-Patient
Clinical Phase I-III
18F / tba
theranostic pair
theranostic pair
The modular and tunable capabilities of our HetSiFA® platform enable the development of more complex dual-targeting theranostics that address unmet but critical clinical needs.